BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-09 13:24 |
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment …
|
English | 2.5 KB | ||
| 2024-08-21 05:00 |
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
|
English | 984.9 KB | ||
| 2024-08-21 05:00 |
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
|
English | 5.5 KB | ||
| 2024-08-20 05:00 |
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK…
|
English | 3.8 KB | ||
| 2024-08-15 07:57 |
BerGenBio ASA: Registration of share capital reduction
|
English | 2.2 KB | ||
| 2024-08-13 05:00 |
BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast
|
English | 3.0 KB | ||
| 2024-07-29 05:00 |
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Sma…
|
English | 4.8 KB | ||
| 2024-06-26 15:35 |
BerGenBio ASA: Grant of share options
|
English | 106.1 KB | ||
| 2024-06-26 15:35 |
BerGenBio ASA: Grant of share options
|
English | 3.7 KB | ||
| 2024-06-03 16:02 |
BerGenBio ASA - Registration of reverse share split
|
English | 1.7 KB | ||
| 2024-05-30 05:00 |
BerGenBio ASA - Ex. reverse share split and change of ISIN today
|
English | 1.5 KB | ||
| 2024-05-29 05:00 |
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
|
English | 937.3 KB | ||
| 2024-05-29 05:00 |
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
|
English | 5.0 KB | ||
| 2024-05-28 13:11 |
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and S…
|
English | 6.5 KB | ||
| 2024-05-28 12:00 |
BerGenBio ASA - Key information relating to the reverse share split and change …
|
English | 2.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
